OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2022
(2)
2023
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Not available
S-EPMC9663323
|
biostudies-literature
Cite
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced
ALK
-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
Not available
S-EPMC10070922
|
biostudies-literature
Cite
Long-Term Efficacy and Safety of Entrectinib in
ROS1
Fusion-Positive NSCLC.
Not available
S-EPMC9160474
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
